华大智造: 2025年半年度报告摘要

Core Viewpoint - Shenzhen BGI Genomics Co., Ltd. reported a decline in revenue and net profit for the first half of 2025, indicating challenges in its operational performance [1]. Financial Performance - Total assets at the end of the reporting period were approximately CNY 10.26 billion, a decrease of 0.55% compared to the end of the previous year [1]. - Operating revenue for the period was approximately CNY 1.11 billion, down 7.90% from CNY 1.21 billion in the same period last year [1]. - The total profit for the period was a loss of approximately CNY 158.27 million, an improvement from a loss of CNY 262.27 million in the previous year [1]. - Net profit attributable to shareholders was a loss of approximately CNY 103.54 million, compared to a loss of CNY 298.23 million in the same period last year [1]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of approximately CNY 202.58 million, compared to a loss of CNY 324.37 million in the previous year [1]. - Cash flows from operating activities showed a loss of approximately CNY 150.06 million, an improvement from a loss of CNY 577.65 million in the previous year [1]. Shareholder Information - The total number of shareholders at the end of the reporting period was 13,505 [2]. - Major shareholders included Shenzhen BGI Technology Holdings Group Co., Ltd. with a 36.73% stake and Tibet Huazhan Venture Capital Co., Ltd. with a 9.95% stake [2][3].